Oncbiomune to Advance Ovarian Cancer Vaccine into Clinical Trials

Oncbiomune to Advance Ovarian Cancer Vaccine into Clinical Trials
OncBioMune Pharmaceuticals is advancing its investigative ovarian cancer vaccine OvcaVax into human clinical trials to test its safety and efficacy in the adjuvant (after surgery) setting. OncBioMune announced it will meet in coming weeks to discuss trial protocol, location, and budget. OvcaVax works similarly to the company's experimental vaccine ProscaVax, which targets the PSA protein in prostate cancer patients. But in this case, the new vaccine immunizes patients against the cancer antigen 125 (CA-125), a protein that is highly elevated in ovarian cancer cells. OncaVax combines the CA-125 protein with two immune system activators,  interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). The strategy is expected to boost immune activity against all cancer cells that are positive for the CA-125 protein. "Recently, we collected very compelling data on ProscaVax eliciting an increased immune response and slowing tumor progression in prostate cancer and believe the same is possible in late-stage ovarian cancer, where women are left with very few therapeutic options,” Dr. Jonathan Head, CEO of OncBioMune, said in a press release. OncBioMune will be meeting shortly with the contract research organization Theradex Oncology to determinate a tria
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *